Screener
NewAmsterdam Pharma Company NAMS Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: NewAmsterdam Pharma Company’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333824
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Prepayments and other receivables | 23,996 | 38,138 |
| Marketable securities, current | 209,703 | 146,239 |
| Restricted cash | 1,357 | 1,321 |
| Total current assets | 659,207 | 675,700 |
| Marketable securities, net of current portion | 44,409 | 92,609 |
| Property, plant and equipment, net | 411 | 383 |
| Operating right of use asset | 82 | 185 |
| Intangible assets | 343 | 407 |
Item 1. Financial Statements.
FAQ
- What is NewAmsterdam Pharma Company's total current assets?
- NewAmsterdam Pharma Company (NAMS) reported total current assets of $659.21M in Q2 2026.
- How has NewAmsterdam Pharma Company's total current assets changed year-over-year?
- NewAmsterdam Pharma Company's total current assets decreased by 14.4% year-over-year, from $769.85M to $659.21M.
- What is the long-term trend for NewAmsterdam Pharma Company's total current assets?
- Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's total current assets has grown at a 12.2% compound annual growth rate (CAGR), from $477.98M to $675.7M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about NewAmsterdam Pharma Company's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude